<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737382</url>
  </required_header>
  <id_info>
    <org_study_id>M18OSI</org_study_id>
    <nct_id>NCT04737382</nct_id>
  </id_info>
  <brief_title>Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.</brief_title>
  <acronym>OSIRIS</acronym>
  <official_title>Osimertinib Resistance Analysis in Patients With EGFR Mutation Positive Non-small-cell Lung Carcinoma That Have Progressed on Osimertinib Treatment'</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Initially, patients with EGFR mutation positive NSCLC respond well to osimertinib, a third&#xD;
      generation EGFR tyrosine kinase inhibitor (TKI), but eventually progress. Upon progression&#xD;
      multiple resistance mechanisms have been described and new therapeutic strategies are being&#xD;
      developed to target these resistance mechanisms. Thorough and complete osimertinib resistance&#xD;
      analysis enables optimal treatment decision making and might identify new targets for&#xD;
      molecular treatment, thereby potentially improving patient outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initially, patients with EGFR mutation positive NSCLC respond well to osimertinib, a third&#xD;
      generation EGFR tyrosine kinase inhibitor (TKI), but eventually progress. Upon progression,&#xD;
      three main resistance mechanisms can be found (1, 2): 1) alteration of the drug target by&#xD;
      secondary or tertiary EGFR mutations (e.g. C797S mutation in the EGFR kinase domain), 2)&#xD;
      alteration of downstream signal transduction proteins (e.g. KRAS mutation / amplification)&#xD;
      and 3) bypass track resistance like MET or HER2 amplification. A fourth, less frequent,&#xD;
      mechanism involves morphological alterations: dedifferentiation by epidermal-mesenchymal&#xD;
      transition (EMT) or change to small-cell-lung carcinoma (SCLC), including RB1 loss.&#xD;
&#xD;
      New therapeutic strategies are being developed to target these resistance mechanisms and&#xD;
      reports have been published about successful treatment of HER2 and MET amplification. Drugs&#xD;
      targeting the C797S mutation are entering the clinic.&#xD;
&#xD;
      Next Generation Sequence (NGS) technology rapidly evolves and it is now feasible to analyse&#xD;
      broad panels of genetic alterations in tumor tissue as well as in circulating tumor DNA&#xD;
      (ctDNA).&#xD;
&#xD;
      ctDNA based T790M detection is a valid method to test for resistance to first or second&#xD;
      generation EGFR TKI's and the ctDNA based technique is increasingly being used for patients&#xD;
      with progression on the third generation EGFR TKI osimertinib. Actually, the distribution of&#xD;
      osimertinib resistance mechanisms, as known to date, largely comes from ctDNA based datasets,&#xD;
      because biopsy based analyses are scarce. Due to impaired sensitivity of ctDNA based analyses&#xD;
      when compared to tissue based analysis, especially for copy number variations, these reports&#xD;
      might be misleading and lead to suboptimal treatment. Early reports of tumor samples obtained&#xD;
      after progression on first / second generation EGFR TKI's have shown that ctDNA and tumor&#xD;
      based drug resistance analyses can be concordant or disconcordant and that the tests should&#xD;
      be regarded as complimentary [Oxnard et al].&#xD;
&#xD;
      Sensitivity and specificity of ctDNA and biopsy based drug resistance analysis after&#xD;
      osimertinib treatment and how these tests behave within individual patients are unknown.&#xD;
&#xD;
      Thorough and complete osimertinib resistance analysis enables optimal treatment decision&#xD;
      making and might identify new targets for molecular treatment, thereby potentially improving&#xD;
      patient outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Anticipated">August 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 22, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EGFR TKI resistance analysis on tumor biopsies and ctDNA</measure>
    <time_frame>Trough study completion, an average of 2 years</time_frame>
    <description>Complete osimertinib resistance analysis in tissue and plasma for all patients in the Netherlands that progress on osimertinib treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommendation for subsequent treatment</measure>
    <time_frame>Trough study completion, an average of 2 years</time_frame>
    <description>Evaluation of these results in an MTB meeting and recommendations for subsequent treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate recommended and actually treatment</measure>
    <time_frame>Trough study completion, an average of 2 years</time_frame>
    <description>Number of patients with concordant recommended and actually provided subsequent treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate plasma and tumor tissue</measure>
    <time_frame>Trough study completion, an average of 2 years</time_frame>
    <description>Number of patients with concordance in osimertinib resistance in plasma using ctDNA and in tumor tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate success rate</measure>
    <time_frame>Trough study completion, an average of 2 years</time_frame>
    <description>To evaluate the success rate of molecular profiling on tumor tissue and ctDNA (test successfully performed or not).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non-small-cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Biopsy and blood</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A histological core biopsy of a tumor lesion and a blood sample for ctDNA analysis will be collected</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>The formalin fixed material will be processed for molecular analysis in a clinically validated diagnostic pipeline according to ISO 15189 or other acceptable standard</description>
    <arm_group_label>Biopsy and blood</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ctDAN analysis</intervention_name>
    <description>ctDNA analysis will be performed using the AVENIO ctDNA targeted kit according to the guidelines from the manufacturer with respect to isolation, library preparation and bioinformatics analysis.</description>
    <arm_group_label>Biopsy and blood</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic NSCLC, characterized by a sensitizing EGFR&#xD;
             mutation.&#xD;
&#xD;
             2. Progressive disease, as assessed by the treating physician during osimertinib&#xD;
             monotherapy.&#xD;
&#xD;
             3. Eligible for subsequent treatment. 4. Willing to undergo a histological biopsy and&#xD;
             withdrawal of a blood sample for ctDNA analysis.&#xD;
&#xD;
             5. Technically possible to take a histological biopsy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - 1. Osimertinib discontinuation before blood draw and / or histological tumor biopsy.&#xD;
&#xD;
        2. Initiation of a new line of anticancer therapy before blood draw and / or histological&#xD;
        tumor biopsy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J de Langen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute-Antoni van Leeuwenhoek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>J de Langen, MD, PhD</last_name>
    <phone>0031205129111</phone>
    <email>j.d.langen@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>M Jebbink</last_name>
    <phone>0031205129111</phone>
    <email>m.jebbeink@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute-Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J de Langen, MD, PhD</last_name>
      <phone>00315129111</phone>
      <email>j.d.langen@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>M Jebbink</last_name>
      <phone>00315129111</phone>
      <email>j.jebbink@nki.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S Hashemi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A vd Wekken, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L Hendriks, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud Universitair Medisch Centrum</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M vd Heuvel, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC, Universitair Medisch Centrum Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Paats, Md, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osimertinib</keyword>
  <keyword>EGFR positive NSCLC</keyword>
  <keyword>Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

